Repeated dose toxicity study of Vibrio cholerae-loaded gastro-resistant microparticles

References

• Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. The global burden of cholera. Bull World Health Organ, 2012;90:209–18
   PubMed Web of Science ®Google Scholar
• Andersen H, Larsen S, Spliid H, Christensen ND. Multivariate statistical analysis of organ weights in toxicity studies. Toxicology, 1999;2–3:67–77
   Google Scholar
• Año G, Esquisabel A, Pastor M, Talavera A, Cedré B, Fernández S, Sifontes S, Aranguren Y, Falero G, García L, et al. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae. Vaccine, 2011;34:5758–64
   Web of Science ®Google Scholar
• Año G, García HM, Valmaseda T, Cedré B, Pino Y, Ancheta O, Pérez JL, García L, Talavera A. Antigenicity and immunogenicity of inactivated Vibrio cholerae strain. Biotech Apl, 2003;20:9–13
   Google Scholar
• Cevher E, Orhan Z, Mülazımoğlu L, Şensoy D, Alper M, Yıldız A, Özsoy Y. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres. Int J Pharm, 2006;2:127–35
   Google Scholar
• Chaignat CL, Monti V. Use of oral cholera vaccine in complex emergencies: What next? Summary report of an expert meeting and recommendations of WHO. J Health Popul Nutr, 2007;2:244–61
   Google Scholar
• Chaignat CL, Monti V, Soepardi J, Petersen G, Sorensen E, Narain J, Kieny MP. Cholera in disasters: Do vaccines prompt new hopes? Expert Rev Vaccines, 2008;4:431–5
   Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer’s patches. J Control Release, 1990;11:205–14
   Web of Science ®Google Scholar
• European Council. 2010. European Pharmacopoeia 7.0. Strasbourg: Council of Europe, European Directorate for the Quality of Medicines and Healthcare
   Google Scholar
• García Sánchez HM, García Imia LG, Talavera Coronel A. Estandarización y evaluación del ensayo vibriocida modificado. Rev Cubana Med Trop, 1999;3:156–9
   Google Scholar
• Grupo Nacional de Laboratorios Clínicos (MINSAP). 1969. Manual de Técnicas para Laboratorio Clínico. La Habana: Editorial Ciencia y Técnica
   Google Scholar
• Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm, 2005;1–2:223–34
   Google Scholar
• ICH Expert Working Group. 2011. Preclinical safety evaluation of biotechnology derived pharmaceuticals S6 (R1). Step 4. Part I. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002828.pdf. Accessed 11 June 2013
   Google Scholar
• Kha TC, Nguyen MH, Roach PD. Effects of spray drying conditions on the physicochemical and antioxidant properties of the Gac (Momordica cochinchinensis) fruit aril powder. J Food Eng, 2010;3:385–92
   Google Scholar
• López Y, Infante JF, Sifontes S, Diaz D, Pérez V, Año G, Hernández T, Fernández S, Castaño JL, Cedré B, et al. Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats. Vaccine, 2011;19:3596–9
   Google Scholar
• Mata E, Igartua M, Patarroyo ME, Pedraz JL, Hernández RM. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci, 2011;1–2:32–40
   Google Scholar
• Pastor M, Esquisabel A, Talavera A, Año G, Fernández S, Callicó A, Falero G, Pedraz JL. An approach to a cold chain free oral cholera vaccine: In vitro and in vivo characterization of Vibrio cholerae gastro-resistant microcapsules. Int J Pharm, 2013;448:247–58
   PubMed Web of Science ®Google Scholar
• Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, González L, Falero G, Talavera A, Pérez O, García L, et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine, 2009;2:205–12
   Google Scholar
• Pérez JL, García LG, Talavera A, Oliva R, Balmaceda T, Año G, Pérez O, Sierra G. Passive protection of serum from volunteers inoculated with attenuated strain 638 of Vibrio cholerae O1 in animal models. Vaccine, 2000;19:376–84
   PubMedGoogle Scholar
• Porras D, Bacardí D, Aldana L, Merino N, Amaya N, Suárez R, Vázquez A, Valenzuela C, Rojo C, Milián G, et al. Evaluación toxicológica en ratas Sprague-Dawley de Interleuquina-2 y del candidato vacunal FPCR3, terapia combinada en pacientes con SIDA. R Toxicol, 2004;1:31–7
   Google Scholar
• Raffin RP, Jornada DS, Ré MI, Pohlmann AR, Guterres SS. Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: Effect of the scale of production and process validation. Int J Pharm, 2006;1:10–18
   Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol, 2009;1:23–32
   Web of Science ®Google Scholar
• Rice-Ficht A, Arenas-Gamboa A, Kahl-McDonagh M, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol, 2010;1:106–12
   Google Scholar
• Salvador A, Igartua M, Hernández RM, Pedraz JL. An overview on the field of micro- and nanotechnologies for synthetic peptide-based vaccines. J Drug Delivery, 2011;2011:1–18
   Google Scholar
• Sifontes-Rodríguez S, Infante-Bourzac JF, Diaz-Rivero D, Lopez-Feria Y, Pérez-Pérez M, Sosa-Roble E, Pérez-Amat V, López-Hernández Y, Álvarez-Figueredo E, Martínez-Rodríguez JC, et al. Repeated dose toxicity study of a live attenuated oral cholera vaccine in Sprague Dawley rats. Arch Med Res, 2009;7:527–35
   Google Scholar
• Talavera A, Año G, Pino Y, Castaño J, Uribarri E, Riverón L, Gil S, Fernández S, Cedré B, Valmaseda T, et al. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Vaccine, 2006;16:3381–7
   Google Scholar
• WHO. Cholera 2011. Wkly Epidemiol Rec, 2012;31–32:289–304
   Google Scholar